Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2026 07:00 ET | Source: CytomX Therapeutics Inc.

CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - -...
March 13, 2026 09:54 ET | Source: Junshi Biosciences

Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates

Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates.
March 13, 2026 09:15 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline Access the Akari CEO Corner here TAMPA, Fla....
March 13, 2026 07:35 ET | Source: Research and Markets

Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Tivdak Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
March 12, 2026 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025...
March 10, 2026 06:45 ET | Source: BioNTech SE

BioNTech veröffentlicht Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 sowie Informationen zur Geschäftsentwicklung

BioNTech erwartet ein Jahr mit zahlreichen wertrelevanten Meilensteinen (Katalysatoren) mit sechs Datenveröffentlichungen aus der späten klinischen Entwicklung, welche Immunmodulatoren,...
March 10, 2026 06:45 ET | Source: BioNTech SE

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on...
March 10, 2026 06:33 ET | Source: BioNTech SE

BioNTech und Mitgründer kündigen Pläne für neues Mitgründer-geführtes Unternehmen zur Entwicklung von mRNA-Innovationen der nächsten Generation an, während BioNTech auf dem Weg zu einem Multi-Produkt-Unternehmen bis 2030 voranschreitet

BioNTech stärkt strategische Ausrichtung auf die wachsende spätklinische Pipeline mit Immunmodulator-, Antikörper-Wirkstoff-Konjugat- und mRNA-Kandidaten BioNTech-Mitgründer Ugur Sahin und Özlem...
March 10, 2026 06:33 ET | Source: BioNTech SE

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidatesBioNTech co-founders Ugur Sahin and Özlem Türeci will...
March 10, 2026 05:14 ET | Source: Research and Markets

Elahere (AbbVie: mirvetuximab soravtansine-gynx) Market Research Report 2026: Epidemiology, Competitive Landscape, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Elahere Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...